Blue Sphere Corp. (OTCQB: BLSP) is on the cusp of breaking ground on two significant electrical production plants in the United States, using Anaerobic Digestion technology.� Blue Sphere�� plants located in Charlotte, North Carolina and Johnston, Rhode Island are expected to produce 5.2 MW and 3.2 MW of electricity daily.� Blue Sphere�� management believes they are at the forefront of a technological shift that will change how the United States will process waste and produce a substantial amount of its energy.� There are many practical and regulatory factors that point to success for Blue Sphere�� initiatives.
The CEO of Blue Sphere, Shlomi Palas, had a good explanation of Blue Sphere�� business plan in a recently published interview.� ��lue Sphere develops, builds and operates facilities which use organic waste to produce clean energy. Blue Sphere is positioned in a multibillion dollar arena which is currently serviced by very few and small-scale competitors. The endless supply of waste, which we call ��he new oil fields�� the new strict Federal and State legislation to divert organic waste from landfills, the already-in-force legislation to substitute fossil energy with renewable energy, the Federal and State incentives for the activities above, all these tectonic movements are the power behind Blue Sphere�� raison d���re. Blue sphere has an objective of building a portfolio of 60 MW high yield assets with an IRR greater than 15% with-in the next 5 years.���/p>
5 Best Healthcare Equipment Stocks To Watch For 2015: Celldex Therapeutics Inc(CLDX)
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The company?s other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors. Its additional clinical and preclinical programs consist of CDX-1401, an Antigen Presenting Cells Targeting Technology program in Phase I/II clinical trial to tr eat multiple solid tumors; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor in Phase I clinical for treating cancer, autoimmune disease, and transplant. The company?s preclinical products include CDX-1135, a molecule for treating renal disease; and CDX-014, a human monoclonal antibody-drug conjugate for the treatment of ovarian and renal cancer. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; Thomas Jefferson University; 3M Company; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Advisors' Opinion:- [By John Udovich]
While the Twitter IPO has been grabing everyone�� attention, biotech IPOs continue to dominate both biotech and IPO news with Karyopharm Therapeutics Inc (NASDAQ: KPTI) going public yesterday and�Relypsa (NASDAQ: RLYP), TetraLogic Pharmaceuticals (NASDAQ: TLOG), Vital Therapies (NASDAQ: VTL) and Xencor (NASDAQ: XNCR) filing to go public in the near future�(despite the sector producing some�ugly charts�for the month of October) plus�another small cap called TNI BioTech (OTCMKTS: TNIB) has also been producing a steady flow of news:
Karyopharm Therapeutics Debuts. Yesterday, small cap Karyopharm Therapeutics, which is working on a drug that aids the body�� natural tumor-suppressing proteins,�debuted at the top of�its range to raise $109 million in an upsized�offering of 6.8 million shares at $16 apiece with shares closing at $16.81. It should be noted that Karyopharm Therapeutics��lead drug candidate (Selinexor) is in early-stage clinical trials�and the company lost�lost nearly $12.5 million on revenue of $366,000 during the first six months of this year. Biotech IPOs by Region. On an interesting note, Luke Timmerman, the National Biotech Editor of Xconomy, has written a�good�article tracking biotech or life sciences IPOs by region. By his count, Boston is home to eight of the 45 (18%) of the life sciences IPOs this year (its companies have also�raised the most money - about $770 million)�plus�the New York/northern New Jersey region is also home to�eight. San Diego�came in third with six IPOs followed by San Francisco with five while only five of the 45 biotech IPOs�came from outside the�US (Three from Israel and two from Europe). However, the above figures may change as by his account, there are 15 additional biotech companies in line to go public. More Biotechs Set IPO Terms. The small cap biotech space is about to be joined by a few new additions as a couple of biotechs file to go public�over the past�week or so: Relypsa, which is d - [By Keith Speights]
Buy, buy
Celldex Therapeutics (NASDAQ: CLDX ) benefited from a couple of "buy" recommendations this week. Many investors appeared to have listened to the advice -- shares jumped 36% for the week.
10 Best Clean Energy Stocks To Buy Right Now: Super Micro Computer Inc.(SMCI)
Super Micro Computer, Inc., together with its subsidiaries, develops and provides high performance server solutions based on modular and open-standard architecture. The company offers a range of rackmount, workstation, storage, graphic processing unit, and blade server systems, as well as subsystems and accessories used by distributors, original equipment manufacturers, and end customers to assemble server systems. It provides server options with single, dual, and quad CPU capability supporting Intel Pentium and Xeon multi-core architectures; and server systems based on AMD dual and quad Opteron. The company also offers server subsystems and accessories, including server boards, and chassis and power supplies. In addition, it sells other system accessories, such as microprocessors, memory, and disc drives. The company sells its server systems, and server subsystems and accessories through distributors, including value added resellers, system integrators, and original equip ment manufacturers, as well as through its direct sales force primarily in the United States, Europe, and Asia. Super Micro Computer, Inc. was founded in 1993 and is headquartered in San Jose, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Super Micro Computer (NASDAQ: SMCI) shares were also up, gaining 11.50 percent to $21.13 after the company reported upbeat FQ3 results and issued a strong Q4 forecast.
- [By Seth Jayson]
Super Micro Computer (Nasdaq: SMCI ) reported earnings on April 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q3), Super Micro Computer missed estimates on revenues and beat expectations on earnings per share.
10 Best Clean Energy Stocks To Buy Right Now: Windstream Corporation(WIN)
Windstream Corporation provides communications and technology solutions in the United States. The company offers various solutions, including IP-based voice and data services, multiprotocol label switching (MPLS) networking, data center and managed services, hosting services, and communications systems to businesses and government agencies. It also provides high-speed Internet, voice, and digital television services to residential customers primarily located in rural areas. The company?s data services include data center and managed hosting, MPLS networking, and dedicated access, as well as high-speed Internet to business customers; integrated solutions consist of multiple voice and data services delivered over an IP connection; voice services comprise local and long distance, call waiting, caller identification, and voicemail; and special access services include point-to-point switching arrangements for voice and data traffic. In addition, it provides wholesale services, which primarily include voice and data services on a wholesale basis to other carriers; usage sensitive services to long distance companies; and other local exchange carriers for access to the network in connection with the completion of long-distance calls, as well as reciprocal compensation received from wireless and other local connecting carriers for the use of its facilities. As of June 30, 2011, the company served approximately 3.3 million access lines, 1.3 million high-speed Internet customers, and operated approximately 60,000 fiber route miles. Windstream Corporation is based in Little Rock, Arkansas.
Advisors' Opinion:- [By David Dittman]
Question: Is Windstream Holdings (NYSE: WIN) going to continue its dividend?
Answer: Windstream is trading near a four-year low as I type. Management has stuck to the current dividend rate, noting that it’s a big part of the investment case for the stock.
- [By Garrett Cook]
Windstream Holdings (NASDAQ: WIN) shares shot up 11.30 percent to $11.72 after the company announced its plans to spin off assets into publicly traded REIT.
- [By David Dittman]
Question: You recently recommended pulling the plug on Windstream Holdings Inc (NYSE: WIN) and dropped it from the UF Portfolio.
In reading that commentary and other news, I couldn’t find anything distinctive that had changed at Windstream. Was this a case of hoping for good news that never comes and finally giving up, or are you expecting some unexpected shoe to drop?
10 Best Clean Energy Stocks To Buy Right Now: Real Goods Solar Inc (RGSE)
Real Goods Solar, Inc., incorporated on January 29, 2008, is a solar energy company. The Company serves commercial, residential, and utility customers. The Company provides a solar solution, from design, financing, permitting and installation to ongoing monitoring, maintenance and support. The Company offers free home solar quotes, as well as solar system financing, design, engineering, permitting, installation, rebate acquisition, maintenance, and monitoring. Effective May 14, 2014, the Company acquired Elemental Energy LLC, doing business as Sunetric.
The Company�� solar power installation services are available in California, Colorado, Connecticut, Delaware, Massachusetts, Missouri, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. The Company's customers include homeowners, small to large businesses and corporations, universities and schools, and government agencies, such as Aetna Insurance, Stop & Shop, Timex, St. Louis Housing Authority, and Yale University.
Advisors' Opinion:- [By Anna Prior]
Real Goods Solar Inc.(RGSE) said it has agreed to raise about $7 million in a private placement financing transaction. Under the terms of the agreement, RGS will issue units consisting of an aggregate of about 2.9 million shares of its Class A common stock and warrants to purchase up to 1.31 million additional shares, at a price of $2.40 a unit. Shares fell 9.7% to $2.62 premarket.
10 Best Clean Energy Stocks To Buy Right Now: Alpha Natural Resources inc. (ANR)
Alpha Natural Resources, Inc., together with its subsidiaries, engages in producing, processing, and selling steam and metallurgical coal in the United States. The company has mining operations in Virginia, West Virginia, Pennsylvania, Kentucky, and Wyoming. As of December 31, 2011, it owned or leased approximately 4.7 billion tons of proven and probable coal reserves; and operated 145 mines in northern and central Appalachia and the Powder River basin. The company is also involved in repairing and reselling equipment and parts used in surface mining; manufacturing particulate scrubbers and filters for underground diesel engine applications; rebuilding underground mining equipment; and providing coal and environmental analysis, and degassing services. In addition, it engages in the sale of non-strategic assets, such as timber, gas, and oil rights, as well as the lease and sale of non-strategic surface properties and reserves; coal brokerage; and road construction business. The company serves electric utilities, steel and coke producers, industrial customers, and energy traders and brokers. Alpha Natural Resources, Inc. was founded in 2002 and is based in Abingdon, Virginia.
Advisors' Opinion:- [By Aimee Duffy]
Dollars for bills
Peabody Energy (NYSE: BTU ) ��$5.5 million CONSOL Energy (NYSE: CNX ) ��$3.9 million Alpha Natural Resources (NYSE: ANR ) ��$2.6 million Arch Coal (NYSE: ACI ) ��$1.8 million Patriot Coal (NASDAQOTH: PCXCQ ) ��$1.1 million�
For the full-year 2012, the coal lobby had these big spenders to thank:Compared to the lobbying dollars its fossil fuel cousin big oil is spending, these numbers aren't that high. Given that the industry is in dire straits ��Patriot Coal has already gone bankrupt ��one would almost expect the numbers to be higher. But perhaps without these lobbying efforts, things would be far worse for coal. The coal lobby has risen steadily after a big uptick between 2004 and 2005, so let's see what issues are garnering the most cash these days.
10 Best Clean Energy Stocks To Buy Right Now: Medical Properties Trust Inc (MPW)
Medical Properties Trust, Inc., incorporated on August 27, 2003, is a self-advised real estate investment trust (REIT) focused on investing in and owning net-leased healthcare facilities. The Company conducts substantially all of its business through MPT Operating Partnership, L.P. The Company acquires and develops healthcare facilities and leases the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear the costs associated with the property. The Company also makes mortgage loans to healthcare operators collateralized by their real estate assets. In addition, the Company selectively makes loans to certain of its operators through its taxable REIT subsidiaries. In September 2013, Medical Properties Trust Inc completed the acquisition of the real estate of three acute care hospitals operated by IASIS Healthcare LLC.
As of February 18, 2013, the Company's portfolio consists of 82 properties: 69 facilities (of the 74 facilities that the Company owns) are leased to 23 tenants, five are under development, and the remainder are in the form of mortgage loans to three operators. The Company's owned facilities consist of 27 general acute care hospitals, 24 long-term acute care hospitals, 15 inpatient rehabilitation hospitals, two medical office buildings, and six wellness centers. The non-owned facilities on which the Company has made mortgage loans consist of three general acute care facilities, two long-term acute care hospitals, and three inpatient rehabilitation hospitals. At December 31, 2012, no one property accounted for more than 5% of the Company's total assets.
At December 31, 2012, the Company had leases with 22 hospital operating companies, eight mortgaged loans, six under development, and one property under re-development covering 82 facilities. Ernest leased 12 of these facilities pursuant to a master lease agreement. The master lease agreement has a 20-year term with three five-year extension options and provides for ! an initial rental rate of 9%, with consumer price-indexed increases, limited to a 2% floor and 5% ceiling annually thereafter. At December 31, 2012, these facilities had an average remaining lease term of approximately 19 years. In addition to the master lease, the Company holds a mortgage loan on four facilities owned by affiliates of Ernest.
Affiliates of Prime Healthcare Services, Inc. (Prime) leased 11 facilities pursuant to master lease agreements. The master leases are for 10 years commencing July 3, 2012 and contain two renewal options of five years each. The initial lease rate is generally consistent with the blended average rate of the prior lease agreements. However, the annual escalators, which in the prior leases were limited, have been increased to reflect 100% of CPI increases, along with a 2% minimum floor. The master leases include repurchase options substantially similar to those in the prior leases, including provisions establishing minimum repurchase prices equal to the Company's total investment. In addition to leases, the Company holds mortgage loans on three facilities owned by affiliates of Prime.
Advisors' Opinion:- [By Brad Thomas]
A Bank of America (BOA) downgrade sends Medical Properties Trust (MPW) tumbling. The bank cut the shares to Underperform from Neutral citing the REIT's YTD outperformance relative to the sector overall (it has outpaced healthcare REITs two to one). Put simply, funds from operations "multiple expansion has exceeded fundamental trends." SA contributor Brad Thomas claims MPW is an example of mispriced risk.
- [By Eric Volkman]
It was an impressive quarter for Medical Properties Trust (NYSE: MPW ) . In its Q1 report, revenues amounted to $58 million, up 42% from the $41 million in the same period the previous year. Attributable net profit advanced much more strongly, growing 148% to $26 million ($0.18 per diluted share) from Q1 2012's figure of $11 million ($0.08). Funds from operations -- a key metric for real estate investment trusts -- came in at $35 million ($0.25 per diluted share) on a normalized basis, compared with $22 million ($0.18) in the year-ago quarter.
10 Best Clean Energy Stocks To Buy Right Now: Receptos Inc (RCPT)
Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.
As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.
As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.
Advisors' Opinion:- [By Garrett Cook]
Receptos (NASDAQ: RCPT) shares shot up 38.62 percent to $93.90 after the company announced positive Phase 2 results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis.
No comments:
Post a Comment